AshEse Journal of Medicine and Medical Researches Vol. 2(1), pp. 023-026, November, 2018 ISSN: 2059-1233

© 2018 AshEse Visionary Limited

http://www.ashese.co.uk/medicine-and-medical-researches/blog



Case Report

Photobiomodulator therapy in the glycemic stabilization of diabetes mellitus carrier type 2 patient

Juliano Abreu Pacheco¹*, Adriana Schapochnik², Antônio Cesar M Santiago³ and Andressa Figueiredo⁴

Received October 2018; Accepted November, 2018

The purpose of this study was to perform transcutaneous, non-invasive and Intravascular Irradiation of blood (Ilib) photobiomodulation in the radial artery of the wrist, besides the phototherapeutic complementation in the oral cavity aiming at the short-term control of glycemia in the patient with Diabetes mellitus type 2, in the Hospital of the Cancer of Ribeirão Preto (SP).

Key words: Diabetes mellitus, oncology, laser, photobiomodulation, glycemia

INTRODUCTION

Type 2 diabetes mellitus (DM) is associated with increased insulin resistance and obesity. Concurrent scientific studies have pointed out that certain susceptibility genes are different from the genes associated with type 1 diabetes. It directly binds DM 2 to increased morbidity and mortality from cardiovascular diseases (Ashok Raj et al., 2009). This congruence between DM 2 and cardiovascular diseases leads to the hypothesis that both have the same genetic component and environmental background, and insulin resistance consider both hypotheses one of the main possible antecedents (Ceriello and Motz, 2004). There is a compromised metabolism of all energy substrates, but what will determine the diagnosis of specific alterations will be the plasma glucose test (Wajchenberg et al., 1992). In Type 2 Diabetes mellitus, resistance to it observes insulin stimulated glucose uptake, even with hyperglycemia, and deterioration of this tolerance will depend on the ability of the pancreas to maintain chronic hyperinsulinemia. It associates insulin-stimulated resistance to glucose uptake with several

alterations that increase the risk for cardiovascular disease, glucose intolerance, hyperinsulinemia, hypertriglyceridemia, HDL-c reduction, arterial hypertension and android obesity (Wajchenberg et al., 1992). Both diabetes and cancer are prevalent diseases whose incidence is increasing. For over 50 years, doctors have reported the existence of patients with concurrent diabetes and cancer, a meta-analysis of several studies has showed that some malignancies are more frequent among patients with diabetes (predominantly type 2). The relative risks induced by diabetes are greater (approximately two or more times) for liver, pancreatic and endometrial cancer and minor (approximately 1.2-1.5 times) for colon and rectal, breast, and bladder cancer. As insulin is produced by β-cells in the pancreas and transported through the portal vein to the liver, it exposes both the pancreas and the liver to high concentrations of endogenously produced insulin.

Factors related to diabetes, such as steatosis, non-alcoholic hepatic steatosis and cirrhosis, may also increase susceptibility

¹Odontologist; Research Coordinator of Oncology Hospital Ribeirão Preto; Specialist in Hospital Dentistry; Master's Degree in Intensive Care by IMBES, Brazil

²Physiotherapist; Specialist in Traditional Chinese Medicine; Master's degree in Biophotonics by Uninove, Brazil

³Doctor, Oncologist at Cancer Hospital of Ribeirão Preto, Brazil

⁴Pediatric Endocrinologist at Hospital São Lucas in Ribeirão Preto, Brazil.

^{*}Corresponding author. E-mail: japacheco@hcancerderibeirao.org.br, coepacheco@gmail.com

Source	Number of subjects	Mean age (Years)	Sex(Nimale)	Intervention	before mg/dl (Mean ± SD)	Blood sugar after mg/dl (Mean ± 5D)
Chen, 2000 (Their Des Cit. (Sex. & Print, 1800)	10	67.3	93.3	He Ne laser extravacular irradiation therapy instrument, , 0—40 mw, 632 linim, 60 min	197.1273-8	106.21540
Kovalyova, 2002 Presion.	27	57.3	- 13	ILBI intravenously 2 mW/J =0,63 mm 405-nm 15-30 min	259.74±15.48	255,78±15.3
, KazemiKhoo, 2013 ^(a)	9	60.63	55	ILBI intravenously 1.5 mW, continuous, 405-nm 30 min	190117	165±20
N. KazemiKhop, 2015	24	37	63.7	ILBI intravenously 1.5 mW, continuous, 405-nm and 630 nm 20-30min-one day blue one day red laser therapy	214.71278.99	188.53275.60

Figure 1. Data of different light therapies for DM 2

to liver cancer. In relation to pancreatic cancer, it found a positive association between diabetes and the risk of pancreatic cancer in studies limited to diabetes that appeared at least 5 years before cancer. The results of some epidemiological studies suggest that diabetes can increase mortality among cancer patients (Dres. Giovannucci et al., 2010). And in cases related to photobiomodulation in patients with type 2 diabetes mellitus early or even advanced that when submitted to laser therapy could restore the function of the pancreas and normalize the level of glucose in the blood (Ramdawon, 1999). It reached this conclusion since laser irradiation stimulated and regenerated pancreatic tissues, including Langerhans cells, regardless of disease stage (Ramdawon, 1999). They reported it that the transmembrane ATPase protein was significantly reduced in DM 2 patients due to Na + / K + -ATPase, Ca² +, Mg² + -ATPase (Tiedan, 1992) activated laser irradiation. It has to be suggested that these observational junctions (Ramdawon, 1999; Tiedan, 1992) related to the photointravascular system could condition a new therapy for the control of cellular glycemic levels. This radiation emitted by the Low Power Lasers (LBP) has demonstrated regenerative, analgesic, anti-inflammatory and healing effects and is therefore widely used in the tissue repair process due to the low energy densities used and wavelengths capable of penetrating tissues (Barros et al., 2008; Catão, 2004). And this intravascular laser irradiation would cause regulation of the hemodynamic system in the blood as well as a control over the physiological lysis of leukocytes (Heine, 2007). This intravenous irradiation is a therapeutic biological method that seems adequate to intervene in this hematological system, which would condition the functional connection between the capillaries (the "final flow"), extra-cellular matrix (ECM) and cells. This ECM is located between the capillaries and the cells, and represents a type of molecular filter in which the fibers of the vegetative nerve have their final propagation, establishing a

connection with the nervous and endocrine system (hypothalamus). This molecular selective process facilitates the metabolic changes of the capillaries between cells, especially proteoglycans, glucosaminoglycans, structural proteins such as collagen, elastin and network glycoproteins, such as fibronectin.

There are several defensive cells in ECM that control the synthesis and decomposition of ECM components through a network of cytokines, which during aging and chronic oxidative stress increase the production of free radicals, acidosis and ECM obstruction that increases volume due to the filter function (sieve). Approximately 1.2 million leukocytes from all 1-2 billion leukocytes in the body are disintegrated every second. By this mechanism, a large number of mediators such as cytokines, chemokines, prostaglandins, leukotriens and many others are released into our body. immunomodulators may intervene in the regulation of blood plasma and extra-cellular matrix (ECM) changes. The studies (Heine, 2007) consider that this physiological lysis of leukocytes would be the central problem of all treatments and measures of medicine of regulation, studies materialized by the doctrine "Lehrbuch der biologischen Medizin" (2007). Analogously, pancreatic islets (or islets of Langerhans) are special group of pancreas cells that produce insulin (by beta cells) and glucagon (by alpha cells) that regulate blood glucose in the human body. Recent studies (Darren, 2017) have shown that light irradiation has improved islet function in rats using red light photobiomodulation (630 nm) or infrared light (810 nm) to significantly increase insulin secretion following glycemic testing (Irani et al., 2009; De Meulenaer et al., 2009). These data (Figure 1) suggest a real possibility of light therapy to aid in type 2 diabetes (DM 2). Tests performed with 70% with type 2 diabetic patients submitted to ILIB, with a baseline mean glucose level ranging from 190 mg / dl to 259 mg / dl, showed a significant decrease in glucose level (mean difference

Table 1. Clinical conduct.

Cronology	HbA _{1C} ** (mg/dl)	Capillary Glycemia ¹ (mg/dl)	hyperglycemia	Capillary Glycemia ² (mg/dl)	Variation* (mg/dl)
30/11/2017	164	178	+	145	19
25/01/2018	149	147	+	123	26
08/03/2018	148	147	+	116	31
29/05/2018	126	141	+	47	94

Variation*: There were always in the quarterly periods a variation of the capillary glycemia measured in the pre and post consultation.

HbA1C:** The mean measured by glycated hemoglobin presented greater control of plasma glycemic indexes.

Capillary glycemia¹: Measurement performed fasting without the use of medication prior to laser therapy.

Capillary glycemia²: Measurement performed after laser therapy.

= 14,445, 95% CI: -1.12 to 30.03, p = 0.007; Table below). Comparing previous laser therapy, the aggregate estimate showed a significant decrease in glucose level.

CASE REPORT

A 66-year-old female patient, MSMSB, diagnosed with invasive right breast carcinoma in the year 2003, underwent tumorectomy and axillary emptying in the same year, followed up with therapy, followed by chemotherapy (CT) - 2 CMF cycles (cyclophosphamide, methotrexate and 5-fluoracil), radio and anastrozole. In 2014, another primary CA in the left breast and submitted to the same protocol with the exception of CTX; but maintained at HT with Letrozole, Calcium and Vit D. Patient with type 2 diabetes and regular use of metiformine 500 mg twice daily. In November, 2017, already during the period of hormone therapy was submitted to the Dentistry Service of the Hospital de Cancer for diagnosis and presenting residual symptoms from oncological therapies. In the initial consultation, the use of a superior removable prosthesis and lower teeth under normal conditions, halitosis, hypogeusia related to salt/sweet flavors, PA 13: 8, reported nonspecific discomfort in daily tasks, capillary glycemia 165mg / dl, glycated Hb 167mg / dl and psoriasis. A protocol was promoted by commercial EC laser, DMC brand, useful red / infrared laser emitter power: 100 mW ± 20%, red laser wavelength 660 nm ± 10 nm, photobiomodulator effect, and use of the I / Ilib phototherapy function (Intravascular Laser Irradiation of Blood) in the radial artery of the wrist (Makela, 2005).

Clinical conduct

- i) Before each session, the patient's initial blood pressure was evaluated;
- ii) Hygiene of the oral cavity with chlorhexidine 0.12% by digital friction, using the sterile gauze;
- iii) Measurement of initial capillary glycemia;
- (iv) Application of the Low-Density Laser (LDL) EC laser, DMC brand, useful red emitter laser power: $100 \text{ mW} \pm 20\%$, red laser wavelength $660 \text{ nm} \pm 10 \text{ nm}$, 1joule (10 seconds) -

red 10 seconds at (parotid, sublingual and submandibular) salivary glands, and in the lingual region (lateral border 9 points 1 joule / point and 2 joules on the back);

- v) 15-minute complementary photoenteral therapy (Ilib) in the radial artery of the wrist;
- vi) Final blood pressure measurement;
- vii) Measurement of final capillary glycemia.

See Table 1 for details

DISCUSSION

The result of this meta-analysis suggests that the therapy used influenced the decrease of blood glucose level in type 2 diabetic patients on time. It is suggested that laser irradiation could have an effect on arginine and increase the production of nitric oxide (Makela, 2005). Arginine affects the release of hormones such as glucagon, insulin, prolactin, adrenal catecholamines and growth hormone. This decreases tissue hypoxia, stimulates oxygenation and normalizes tissue metabolism (Brill et al., 2003). This study indicate that in advanced stages phototherapy could restore pancreatic function and normalize blood glucose levels, as a consequence, stimulate and regenerate pancreatic tissues, including Langerhans beta cells (Ramdawon, 1999). That is, the importance of Low Intensity Laser (LBI) for the patient's global recovery in several health specialties is a pleasing methodological reality; and the organic responses are considered beneficial (Pacheco and Bezinelli, 2018) in a variety of different modalities, due to its photobiomodulatory effect, besides emphasizing that it has preponderant connections to neuronal repair and in neurogenesis, not excepting in the formation of new brain cells, but also in the synaptogenesis, which is the formation of new connections between existing brain cells. When the molecule is absorbed by light it allows an increase in cellular metabolism, characterized by stimulation of photoreceptors in the mitochondrial respiratory chain, changes in cellular ATP levels, release of growth factors and collagen synthesis (Posten et al., 2005; Kreisler et al., 2003). In addition to the Intravascular Laser Irradiation of Bloodib function, it triggers an antioxidant system composed of enzymes, the main metallo-enzyme

^{*}During photobiomodulatory therapy the patient did not use metiformine.

^{*}Therapy was performed 15/15 days and final results were collected at the end of 6 months.

superoxide dismutase, or SOD ZnCu, is the major antioxidant agent in the human body (Bellou et al., 2016). However, evidence confirms that the enzymes catalase, peroxidase and ceruloplasmin also absorb the red laser which potentiates other enzymes, which obviously further maximizes the antioxidant property of these enzymes when irradiated in the ILIB process (Bellou et al., 2016).

Conclusion

Throughout the process of this case study, multidisciplinary parameters were established so that the physical responses could correspond to the recovery of the general well-being of the patient. Parallel to the glycemic measurements there was also a significant reduction of the signs and symptoms initially reported that allowed an organic balance of great relevance in the recovery of self-esteem. It is necessary to maintain the lucidity about this study, even though it is known that in this period the bioelectrical and bioenergetic functions favored the mitochondrial respiratory chain with positive responses to the capillary and plasma glycemic indices. However, a new perspective of non-invasive therapy and longevity to be explored opens.

Conflict of interest

The author has not declared any conflict of interest

REFERENCES

- Ashok Raj R, Saravana Kumar A, Gandhimathi R (2009). Hypoglycemic and Hypolipidemic Activity of *Wrightia tinctoria* L. in Alloxan Induced Diabetes in Albino Wistar, India Pharmaceuticals Private, Bangalore, India- 560017. Sree Vidyanikethan College of Pharmacy, Tirupati, Andhra Pradesh, India-517102
- Barros FC, Antunes SA, Figueredo CMS, Fischer RG (2008). Laser de baixa intensidade na cicatrização periodontal. R CiMed Biol. 7:85.
- Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JP (2016). Fatores de risco ambientais e doença de Parkinson: uma análise geral das meta-análises. Parkinsonismo Relat. Disorder. 23:1-9.
- Brill G, Gasparyan L, Makela A (2003). Modification in relationships in the system endothelial cell-blood platelet by low level laser radiation. Laser Florence meeting
- Catão MHCV (2004). Os benefícios do laser de baixa intensidade na clínica odontológica na estomatologia. Rev. Bras. Patol. Oral. 3:214-8.
- Ceriello A, Motz E (2004). Is oxdative stress the patogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revised. Arterioscler Thromb. Vasc Biol. 24(5):816-23.

- Darren R (2017) The Investigation of the Effects of Low Light Laser Therapy on Insulin Secretion in Porcine Islets, a Pilot Study, SPT Angelo State University, San Angelo TX
- De Meulenaer EC, Louchami K, Zhang Y, Bulur N, Sener A, Malaisse WJ (2009). Efeitos de luz infravermelha na liberação de insulina, fluxos catiônicos e celularidade em células produtoras de insulina. Met. Func. Res. Diab. 2:63-70.
- Dres. Giovannucci E, Harlan D, Archer M (2010). Câncer de CA J Clin 2010, © American Cancer Society.
- Heine H (2007). Lehrbuch der biologischen Medizin. Stuttgart: Hippokrates, 3. Auflage
- Irani S, Mohseni Salehi Monfared SS, Akbari-Kamrani M, Ostad SN, Abdollahi M, Larijani B (2009). Efeito da irradiação a laser de baixo nível na função in vitro de ilhotas pancreáticas. Processos de transplante. 41(10):4313-5.
- Kreisler M, Christoffers AB, Willershausen B, d'Hoedt B (2003). Effect of low-level GaAlAs laser irradiation on the proliferation rate of human periodontal ligament fibroblasts: an in vitro study. J. Clin. Periodontol. 30:353-8.
- Makela A (2005). Role of L-arginine in the biological effects of blue light [5968-06]. Proceedings-Spie The International Society For Optical Engineering.
- Pacheco JA, Bezinelli LM (2018). The Photobiomodulatory Therapy and ILIB in the Repair of Encephalic Cisterns and Progressive Cognitive Restoration in a Patient with Traumatic Brain Injury. Med Case Rep. 3:73.
- Posten W, Wrone DA, Dover JS, Arndt KA, Silapunt S, Alam M (2005). Low-level laser therapy for wound healing: mechanism and efficacy. Dermatol. Surg. 31:334-9.
- Ramdawon P (1999). Bioresonance information laser therapy of diabetesmellituse a first clinical experience of the hypoglycemic effect of low level laser terapy and its perspectives, Paper presented at the North American Laser Therapy Association Conference.
- Ramdawon P (1999). Bioresonance information laser therapy of diabetes mellituse a first clinical experience of the hypoglycemic effect of low level laser terapy and its perspectives, Paper presented at the North American Laser Therapy Association Conference.
- Tiedan W (1992). Effects of low-energy He-Ne laser irradiation of extracorporeally circulatory blood on ATPase activities of erythrocyte membrane in patients with IDDM [J]. Laser J. 6:011.
- Wajchenberg BL, Santomauro ATMG, Santos RF (1992). Diabetes Melito insulino-dependente (Tipo II): diagnóstico, etiopatogenia e fisiopatologia. In: Wajchenberg BL, organizador. Tratado de endocrinologia clínica. São Paulo: Roca; pp.706-38.